JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Alfredo Cesario
Pierluigi Granone
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paleari, L.
Right arrow Articles by Granone, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Paleari, L.
Right arrow Articles by Granone, P.
Related Collections
Right arrow Lung - cancer

J Thorac Cardiovasc Surg 2008;136:241-242
© 2008 The American Association for Thoracic Surgery


Letter to the Editor

Factors predicting poor survival after resection of stage IA non–small cell lung cancer

Laura Paleari, PhDa, Patrizia Russo, PhDa, Alfredo Cesario, MD, PhDb,c, Pierluigi Granone, MD, PhDb

a Lung Cancer Unit, National Cancer Research Institute, Genoa, Italy
b Surgical Pathology Unit, Catholic University, Rome, Italy
c Respiratory Unit, IRCCS "San Raffaele", Rome, Italy

The first 20% of the full text of this article appears below.

To the Editor:

We have read with interest the paper by Chang and associates.1Go Interestingly, we observe that the factors considered to predict poor survival after resection of stage IA non–small cell lung cancer (NSCLC) still remain tumor size, gender, age, and extent of resection.

It is true, in fact, that lung cancer staging currently rests on histopathologic and clinical criteria that have only limited power to predict relapse and survival. A major effort to improve the control of NSCLC entails the use of molecular profiling to characterize tumors and provide accurate predictions of the outcome after standard or novel treatments. Moreover, molecular profiling, as we2Go already discussed . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.